Transfer and Multi-task Learning in QSAR Modeling: Advances and Challenges
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Medicinal chemistry projects involve some steps aiming to develop a new drug, such as the analysis of biological targets related to a given disease, the discovery and the development of drug candidates for these targets, performing parallel biological tests to validate the drug effectiveness and side effects. Approaches as quantitative study of activity-structure relationships (QSAR) involve the construction of predictive models that relate a set of descriptors of a chemical compound series and its biological activities with respect to one or more targets in the human body. Datasets used to perform QSAR analyses are generally characterized by a small number of samples and this makes them more complex to build accurate predictive models. In this context, transfer and multi-task learning techniques are very suitable since they take information from other QSAR models to the same biological target, reducing efforts and costs for generating new chemical compounds. Therefore, this review will present the main features of transfer and multi-task learning studies, as well as some applications and its potentiality in drug design projects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
QSAR Modeling: Where have you been? Where are you going to?
Cherkasov, A., Muratov, E. N., Fourches, D., Varnek, A., Baskin, I. I., Cronin, M., Dearden, J., Gramatica, P., Martin, Y. C., Todeschini, R., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm4004285 · Cited by 2,164 · cited 2×
“…methods and algorithms (Sliwoski et al., 2014; Raies and Bajic, 2016), validation techniques (Gramatica and Sangion, 2016), applications (Cherkasov et al., 2014; Fang and Xiao, 2016) as well-challenges and how those have been addressed (Cronin and Schultz, 2003; Arthur, 2008; Dearden et…”
BackgroundMethodVirtual screening of chemical libraries
Shoichet, B. K. (2004) · Nature · doi:10.1038/nature03197 · Cited by 1,425
From machine learning to deep learning: progress in machine intelligence for rational drug discovery
Zhang, L., Tan, J., Han, D., & Zhu, H. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.08.010 · Cited by 760
Caruana, R. (1998) · Learning to Learn · doi:10.1007/978-1-4615-5529-2_5 · Cited by 577
Drug discovery in pharmaceutical industry: productivity challenges and trends
Khanna, I. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.05.007 · Cited by 479 · cited 1×
“…well-known bottlenecks in this process, such as finding out a suitable and validated molecular target, designing and/or discovering of a lead compound, pharmacokinetic and toxicity optimization, besides commercial reasons, efficacy and clinical safety (Khanna, 2012; Medina-Franco et al., 2013).”
BackgroundHow not to develop a quantitative structure–activity or structure–property relationship (QSAR/QSPR)
Dearden, J. C., Cronin, M. T. D., & Kaiser, K. L. E. (2009) · SAR and QSAR in Environmental Research · doi:10.1080/10629360902949567 · Cited by 468
How to Recognize and Workaround Pitfalls in QSAR Studies: A Critical Review
Scior, T., Medina-Franco, J. L., Do, Q.-T., Martinez-Mayorga, K., Yunes Rojas, J. A., & Bernard, P. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709789578213 · Cited by 197
Adverse drug events: database construction and in silico prediction
Cheng, F., Li, W., Wang, X., Zhou, Y., Wu, Z., Shen, J., & Tang, Y. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci4000079 · Cited by 124 · cited 1×
“Analyses on multi-label classification showed that the proposed transfer learning approaches achieved better performance than state-of-art-methods (Pauwels et al., 2011; Liu et al., 2012; Cheng et al., 2013) applied to benchmark datasets.”
MethodVarnek, A., Gaudin, C., Marcou, G., Baskin, I., Pandey, A. K., & Tetko, I. V. (2009) · Journal of Chemical Information and Modeling · doi:10.1021/ci8002914 · Cited by 86
Cited by
Artificial intelligence in drug discovery: recent advances and future perspectives
Jiménez-Luna, J., Grisoni, F., Weskamp, N., & Schneider, G. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1909567 · Cited by 464
Integrating QSAR modelling and deep learning in drug discovery: the emergence of deep QSAR
Tropsha, A., Isayev, O., Varnek, A., Schneider, G., & Cherkasov, A. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00832-0 · Cited by 397
Deep learning in drug discovery: opportunities, challenges and future prospects
Lavecchia, A. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.07.006 · Cited by 353
The transformational role of GPU computing and deep learning in drug discovery
Pandey, M., Fernandez, M., Gentile, F., Isayev, O., Tropsha, A., Stern, A. C., & Cherkasov, A. (2022) · Nature Machine Intelligence · doi:10.1038/s42256-022-00463-x · Cited by 255
“…and their adverse effects 42 , the prediction of small molecule–protein binding 43 , the determination of chemotherapeutic responses of carcinogenic cells 44 , the quantitative estimation of drug sensitivity 45 and quantitative structure–activity relationship (QSAR) modelling 46 , among others.”
Background
Metadata
- Authors
- Simões, R. S., Maltarollo, V. G., Oliveira, P. R., & Honorio, K. M.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2018-02-06
- Volume
- 9
- Pages
- 74-74
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2789796452
- Cited by
- 116
- References
- 9
- FWCI
- 7.46
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.